Ray Dalio
PTGX icon

Ray Dalio’s Protagonist Therapeutics PTGX Stock Holding History

Ray Dalio’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.14M Buy
9,269
+3,993
+76% +$417K ﹤0.01% 818
2026
Q1 		$556K Buy
+5,276
New +$467K ﹤0.01% 868

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Farallon Capital Management
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
RTW Investments
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Johnson & Johnson
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Ray Dalio's PTGX Position: Q2 2026 in Review

Ray Dalio increased its Protagonist Therapeutics (PTGX) stake by 76% in Q2 2026, buying an estimated $417K and bringing the position to 9,269 shares worth $1.14M. The position accounts for ﹤0.01% of the portfolio, ranked #818.

Ray Dalio first reported a position in PTGX in Q1 2026 and has held it in 2 quarters since. 343 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

  • Ray Dalio held 9,269 shares of Protagonist Therapeutics worth $1.14M as of Q2 2026.
  • Ray Dalio bought 3,993 Protagonist Therapeutics shares in Q2 2026, an estimated $417K.
  • Protagonist Therapeutics made up ﹤0.01% of Ray Dalio's portfolio in Q2 2026, its #818 holding.
  • Ray Dalio first reported a position in Protagonist Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 343 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on Bridgewater Associates's 13F filing for Q2 2026, filed 14 Aug 2026.